vs
AerSale Corp(ASLE)与Health Catalyst, Inc.(HCAT)财务数据对比。点击上方公司名可切换其他公司
AerSale Corp的季度营收约是Health Catalyst, Inc.的1.2倍($90.9M vs $74.7M),AerSale Corp净利率更高(5.9% vs -121.9%,领先127.8%),AerSale Corp同比增速更快(-4.0% vs -6.2%),AerSale Corp自由现金流更多($9.8M vs $9.6M),过去两年AerSale Corp的营收复合增速更高(0.2% vs -0.0%)
AerSale Corp总部位于美国佛罗里达州多拉市,是一家面向航空领域的全球供应商,主要为客运及货运航空公司、政府机构、跨国整机制造商与独立维修机构提供商用喷气飞机二手整机、发动机、航空耗材,并提供航空工程服务,同时该公司也是飞机机队回收协会的成员企业。
Catalyst制药公司是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业,专注于开发罕见病治疗药物。其开发的阿米夫斯汀磷酸盐商品名为Firdapse,原本已获FDA批准用于成人兰伯特-伊顿肌无力综合征(LEMS)的治疗,2018年11月又获批可用于6岁及以上儿童LEMS患者。
ASLE vs HCAT — 直观对比
营收规模更大
ASLE
是对方的1.2倍
$74.7M
营收增速更快
ASLE
高出2.2%
-6.2%
净利率更高
ASLE
高出127.8%
-121.9%
自由现金流更多
ASLE
多$138.0K
$9.6M
两年增速更快
ASLE
近两年复合增速
-0.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $90.9M | $74.7M |
| 净利润 | $5.4M | $-91.0M |
| 毛利率 | 34.1% | — |
| 营业利润率 | 7.8% | -115.3% |
| 净利率 | 5.9% | -121.9% |
| 营收同比 | -4.0% | -6.2% |
| 净利润同比 | 99.7% | -340.3% |
| 每股收益(稀释后) | $0.10 | $-1.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
ASLE
HCAT
| Q4 25 | $90.9M | $74.7M | ||
| Q3 25 | $71.2M | $76.3M | ||
| Q2 25 | $107.4M | $80.7M | ||
| Q1 25 | $65.8M | $79.4M | ||
| Q4 24 | $94.7M | $79.6M | ||
| Q3 24 | $82.7M | $76.4M | ||
| Q2 24 | $77.1M | $75.9M | ||
| Q1 24 | $90.5M | $74.7M |
净利润
ASLE
HCAT
| Q4 25 | $5.4M | $-91.0M | ||
| Q3 25 | $-120.0K | $-22.2M | ||
| Q2 25 | $8.6M | $-41.0M | ||
| Q1 25 | $-5.3M | $-23.7M | ||
| Q4 24 | $2.7M | $-20.7M | ||
| Q3 24 | $509.0K | $-14.7M | ||
| Q2 24 | $-3.6M | $-13.5M | ||
| Q1 24 | $6.3M | $-20.6M |
毛利率
ASLE
HCAT
| Q4 25 | 34.1% | — | ||
| Q3 25 | 30.2% | 52.6% | ||
| Q2 25 | 32.9% | — | ||
| Q1 25 | 27.3% | — | ||
| Q4 24 | 31.4% | — | ||
| Q3 24 | 28.6% | 47.5% | ||
| Q2 24 | 28.2% | — | ||
| Q1 24 | 31.8% | — |
营业利润率
ASLE
HCAT
| Q4 25 | 7.8% | -115.3% | ||
| Q3 25 | 4.0% | -22.9% | ||
| Q2 25 | 11.7% | -46.0% | ||
| Q1 25 | -10.1% | -25.4% | ||
| Q4 24 | 5.2% | -22.0% | ||
| Q3 24 | 2.4% | -17.9% | ||
| Q2 24 | -2.4% | -20.8% | ||
| Q1 24 | 5.2% | -30.5% |
净利率
ASLE
HCAT
| Q4 25 | 5.9% | -121.9% | ||
| Q3 25 | -0.2% | -29.1% | ||
| Q2 25 | 8.0% | -50.8% | ||
| Q1 25 | -8.0% | -29.9% | ||
| Q4 24 | 2.9% | -26.0% | ||
| Q3 24 | 0.6% | -19.3% | ||
| Q2 24 | -4.7% | -17.8% | ||
| Q1 24 | 6.9% | -27.6% |
每股收益(稀释后)
ASLE
HCAT
| Q4 25 | $0.10 | $-1.29 | ||
| Q3 25 | $0.00 | $-0.32 | ||
| Q2 25 | $0.18 | $-0.59 | ||
| Q1 25 | $-0.10 | $-0.35 | ||
| Q4 24 | $0.05 | $-0.33 | ||
| Q3 24 | $0.01 | $-0.24 | ||
| Q2 24 | $-0.07 | $-0.23 | ||
| Q1 24 | $0.12 | $-0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $4.4M | $95.7M |
| 总债务越低越好 | $1.3M | $153.3M |
| 股东权益账面价值 | $424.4M | $245.8M |
| 总资产 | $640.5M | $502.6M |
| 负债/权益比越低杠杆越低 | 0.00× | 0.62× |
8季度趋势,按日历期对齐
现金及短期投资
ASLE
HCAT
| Q4 25 | $4.4M | $95.7M | ||
| Q3 25 | $5.3M | $91.5M | ||
| Q2 25 | $5.7M | $97.3M | ||
| Q1 25 | $4.7M | $342.0M | ||
| Q4 24 | $4.7M | $392.0M | ||
| Q3 24 | $9.8M | $387.3M | ||
| Q2 24 | $4.3M | $308.3M | ||
| Q1 24 | $2.6M | $327.8M |
总债务
ASLE
HCAT
| Q4 25 | $1.3M | $153.3M | ||
| Q3 25 | $1.5M | $153.1M | ||
| Q2 25 | $907.0K | $153.0M | ||
| Q1 25 | $1.1M | $382.9M | ||
| Q4 24 | $1.2M | $382.4M | ||
| Q3 24 | $376.0K | $345.0M | ||
| Q2 24 | $522.0K | — | ||
| Q1 24 | $3.5M | — |
股东权益
ASLE
HCAT
| Q4 25 | $424.4M | $245.8M | ||
| Q3 25 | $417.1M | $331.9M | ||
| Q2 25 | $415.9M | $347.5M | ||
| Q1 25 | $406.5M | $376.8M | ||
| Q4 24 | $455.6M | $365.2M | ||
| Q3 24 | $451.5M | $355.0M | ||
| Q2 24 | $449.8M | $357.0M | ||
| Q1 24 | $452.0M | $357.2M |
总资产
ASLE
HCAT
| Q4 25 | $640.5M | $502.6M | ||
| Q3 25 | $646.3M | $587.1M | ||
| Q2 25 | $646.7M | $616.2M | ||
| Q1 25 | $646.1M | $891.5M | ||
| Q4 24 | $604.7M | $858.9M | ||
| Q3 24 | $601.5M | $813.0M | ||
| Q2 24 | $598.7M | $691.7M | ||
| Q1 24 | $571.7M | $695.1M |
负债/权益比
ASLE
HCAT
| Q4 25 | 0.00× | 0.62× | ||
| Q3 25 | 0.00× | 0.46× | ||
| Q2 25 | 0.00× | 0.44× | ||
| Q1 25 | 0.00× | 1.02× | ||
| Q4 24 | 0.00× | 1.05× | ||
| Q3 24 | 0.00× | 0.97× | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $11.4M | $9.9M |
| 自由现金流经营现金流 - 资本支出 | $9.8M | $9.6M |
| 自由现金流率自由现金流/营收 | 10.8% | 12.9% |
| 资本支出强度资本支出/营收 | 1.7% | 0.4% |
| 现金转化率经营现金流/净利润 | 2.11× | — |
| 过去12个月自由现金流最近4个季度 | $-29.1M | $-697.0K |
8季度趋势,按日历期对齐
经营现金流
ASLE
HCAT
| Q4 25 | $11.4M | $9.9M | ||
| Q3 25 | $-8.9M | $-464.0K | ||
| Q2 25 | $19.8M | $-9.0M | ||
| Q1 25 | $-45.2M | $280.0K | ||
| Q4 24 | $37.5M | $-3.5M | ||
| Q3 24 | $10.4M | $6.2M | ||
| Q2 24 | $-15.3M | $1.6M | ||
| Q1 24 | $-21.5M | $10.3M |
自由现金流
ASLE
HCAT
| Q4 25 | $9.8M | $9.6M | ||
| Q3 25 | $-9.8M | $-719.0K | ||
| Q2 25 | $18.6M | $-9.2M | ||
| Q1 25 | $-47.6M | $-390.0K | ||
| Q4 24 | $32.3M | $-3.9M | ||
| Q3 24 | $8.9M | $5.5M | ||
| Q2 24 | $-18.9M | $1.3M | ||
| Q1 24 | $-25.0M | $10.1M |
自由现金流率
ASLE
HCAT
| Q4 25 | 10.8% | 12.9% | ||
| Q3 25 | -13.8% | -0.9% | ||
| Q2 25 | 17.3% | -11.4% | ||
| Q1 25 | -72.4% | -0.5% | ||
| Q4 24 | 34.0% | -4.9% | ||
| Q3 24 | 10.7% | 7.2% | ||
| Q2 24 | -24.6% | 1.7% | ||
| Q1 24 | -27.7% | 13.5% |
资本支出强度
ASLE
HCAT
| Q4 25 | 1.7% | 0.4% | ||
| Q3 25 | 1.3% | 0.3% | ||
| Q2 25 | 1.1% | 0.3% | ||
| Q1 25 | 3.7% | 0.8% | ||
| Q4 24 | 5.6% | 0.5% | ||
| Q3 24 | 1.9% | 0.9% | ||
| Q2 24 | 4.7% | 0.4% | ||
| Q1 24 | 3.9% | 0.3% |
现金转化率
ASLE
HCAT
| Q4 25 | 2.11× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.31× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 13.89× | — | ||
| Q3 24 | 20.52× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -3.42× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASLE
| Products | $57.8M | 64% |
| Maintenance | $23.2M | 26% |
| Leasing Arrangements | $9.9M | 11% |
HCAT
| Recurring Technology | $51.9M | 69% |
| Professional Services | $22.8M | 31% |